Multiple studies have demonstrated that diffuse large B-cell lymphoma (DLBCL) can be divided into subgroups based on their biology; however, these biological subgroups overlap clinically. Using machine learning, we developed an approach to stratify patients with DLBCL into four subgroups based on survival characteristics. This approach uses data from the targeted transcriptome to predict these survival subgroups. Using the expression levels of 180 genes, our model reliably predicted the four survival subgroups and was validated using independent groups of patients. Multivariate analysis showed that this patient stratification strategy encompasses various biological characteristics of DLBCL, and only TP53 mutations remained an independent prognostic biomarker. This novel approach for stratifying patients with DLBCL, based on the clinical outcome of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy, can be used to identify patients who may not respond well to these types of therapy, but would otherwise benefit from alternative therapy and clinical trials.

Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms / Albitar, M.; Zhang, H.; Goy, A.; Xu-Monette, Z. Y.; Bhagat, G.; Visco, C.; Tzankov, A.; Fang, X.; Zhu, F.; Dybkaer, K.; Chiu, A.; Tam, W.; Zu, Y.; Hsi, E. D.; Hagemeister, F. B.; Huh, J.; Ponzoni, M.; Ferreri, A. J. M.; Moller, M. B.; Parsons, B. M.; van Krieken, J. H.; Piris, M. A.; Winter, J. N.; Li, Y.; Xu, B.; Young, K. H.. - In: BLOOD CANCER JOURNAL. - ISSN 2044-5385. - 12:2(2022). [10.1038/s41408-022-00617-5]

Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms

Ponzoni M.;Ferreri A. J. M.;
2022-01-01

Abstract

Multiple studies have demonstrated that diffuse large B-cell lymphoma (DLBCL) can be divided into subgroups based on their biology; however, these biological subgroups overlap clinically. Using machine learning, we developed an approach to stratify patients with DLBCL into four subgroups based on survival characteristics. This approach uses data from the targeted transcriptome to predict these survival subgroups. Using the expression levels of 180 genes, our model reliably predicted the four survival subgroups and was validated using independent groups of patients. Multivariate analysis showed that this patient stratification strategy encompasses various biological characteristics of DLBCL, and only TP53 mutations remained an independent prognostic biomarker. This novel approach for stratifying patients with DLBCL, based on the clinical outcome of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy, can be used to identify patients who may not respond well to these types of therapy, but would otherwise benefit from alternative therapy and clinical trials.
File in questo prodotto:
File Dimensione Formato  
s41408-022-00617-5.pdf

accesso aperto

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Creative commons
Dimensione 1.7 MB
Formato Adobe PDF
1.7 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/153120
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 7
social impact